Archive | May, 2011

PPMI volunteer inspired by friend with PD

WGRZ-TV in Buffalo, NY, speaks with PPMI participant Paul Cohen about being there for his friend with Parkinson's by volunteering for PPMI.

Continue reading...

Stop by the poster featuring PPMI recruitment on Tuesday at the MDS meeting

PPMI will be at the MDS meeting in Toronto, presenting a poster on innovative approaches to recruitment to meet enrollment goals.

Continue reading...

New Version of the PPMI DTI Manual Posted

Version 3.2 of the Diffusion Tensor Imaging Manual has been posted to the PPMI website.

Continue reading...

Poster Presentation from the 2011 Society for Clinical Trials

Dr. Chris Coffey, head of the PPMI Statistics Core, presented an overview of PPMI and showcased the data and specimen availability through PPMI-info at the Society for Clinical Trials annual meeting. Click here to view the poster.

Continue reading...

Issue 1 of the PPMI Subject Newsletter now available

The Spring issue of "PPMI News," the subject newsletter for PPMI, has been distributed to sites. This issue features a study update, an overview of biomarkers, and expresses thanks to the participants who have enrolled in the study.

Continue reading...

Op-ed: Clinical trials a key priority for Michael J. Fox (San Francisco Chronicle)

Michael J. Fox writes about the need for volunteers in clinical research, and MJFF's efforts to speed the cure in the San Francisco Chronicle.

Continue reading...

PPMI 2011 Annual Meeting Summary

The PPMI Annual Meeting recently took place in New York City. Access to the presentations that were made at this event are now available.

Continue reading...

PPMI at Cleveland Clinic featured in The Plain Dealer

Dr. Hubert Fernandez, PI at Cleveland Clinic, and Todd Sherer, MJFF CEO, are interviewed about Parkinson's disease and PPMI. The article highlights research and clinical trials and the efforts to find a cure for PD.

Continue reading...

?-Synuclein Reactive Antibodies as Diagnostic Biomarkers in Blood Sera of Parkinson’s Disease Patients

This recent publication suggests that there may be elevated levels of antibodies acting against alpha-synuclein in the serum of PD patients when compared to controls. This may mean that an immune response to synuclein is occurring. The preliminary data from this paper provides an excellent example of the kind of research that could utilize the PPMI biorepository for further biomarker verification study.

Continue reading...

Differentiated tau/alpha-synuclein ratios in PD patients

This paper suggests that tau and alpha-synuclein levels in CSF may be different in PD patients when compared to individuals with other disorders and controls. The PPMI steering committee already plans to analyze tau and synuclein for this purpose, but this paper provides further rationale for these two substances as viable biomarker leads.

Continue reading...